within Pharmacolibrary.Drugs.ATC.N;

model N04AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 0.5833333333333334,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.034,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0023333333333333335,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Trihexyphenidyl is an anticholinergic medication primarily used in the treatment of Parkinson's disease and drug-induced extrapyramidal symptoms. It acts as a muscarinic acetylcholine receptor antagonist reducing cholinergic activity in the central nervous system. It is an approved drug, still used for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult population treated orally.</p><h4>References</h4><ol><li><p>Yang, Y, et al., &amp; Zou, Q (2019). [Determination of trihexyphenidyl in human plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. <i>Se pu = Chinese journal of chromatography</i> 37(12) 1291–1296. DOI:<a href=&quot;https://doi.org/10.3724/SP.J.1123.2019.05026&quot;>10.3724/SP.J.1123.2019.05026</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34213130/&quot;>https://pubmed.ncbi.nlm.nih.gov/34213130</a></p></li><li><p>Roberts, J, et al., &amp; Bulling, M (1996). The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. <i>British journal of clinical pharmacology</i> 41(4) 331–337. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.1996.32311.x&quot;>10.1046/j.1365-2125.1996.32311.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8730980/&quot;>https://pubmed.ncbi.nlm.nih.gov/8730980</a></p></li><li><p>Brocks, DR (1999). Anticholinergic drugs used in Parkinson&#x27;s disease: An overlooked class of drugs from a pharmacokinetic perspective. <i>Journal of pharmacy &amp; pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</i> 2(2) 39–46. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10952768/&quot;>https://pubmed.ncbi.nlm.nih.gov/10952768</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N04AA01;
